How were Neuren Pharmaceuticals' earnings last quarter?

Neuren Pharmaceuticals Limited (ASX:NEU) released its earnings results on Wednesday, February, 27th. The company reported $0.03 earnings per share (EPS) for the quarter. Neuren Pharmaceuticals had a trailing twelve-month return on equity of 127.30% and a net margin of 67.72%.

What other stocks do shareholders of Neuren Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuren Pharmaceuticals investors own include Macquarie Group (MQG) , Magellan Financial Group (MFG) , Medlab Clinical (MDC) , FBR (FBR) , Embark Early Education (EVO) , Dacian Gold (DCN) , Constellation Technologies (CT1) , Afterpay (APT) and Alkane Resources (ALK) .

ASX:NEU

Neuren Pharmaceuticals (NEU) Stock Price, News & Analysis

→ The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad)

Free NEU Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 57,935 shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Neuren Pharmaceuticals alerts:

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Neuren Pharmaceuticals Stock (ASX:NEU)

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

NEU Stock News Headlines

April 3, 2024 | msn.com

ASX loses 1.3% on back of Wall Street decline, gold price hits new high and the world's richest people are getting richer — as it happened

April 1, 2024 | finance.yahoo.com

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

April 16, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

March 26, 2024 | uk.finance.yahoo.com

20 Biggest Health Care Companies in Australia, 2024

March 18, 2024 | fool.com.au

The best ASX shares to invest $500 in right now

March 11, 2024 | fool.com.au

$10k of savings? I'd buy these ASX 200 shares to grow my money

March 3, 2024 | finance.yahoo.com

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

February 29, 2024 | fool.com.au

What's with the Neuren Pharmaceuticals share price today?

April 16, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

February 28, 2024 | msn.com

Inflation remains at two-year low, Optus sacks extra 200 staff, Sony terminates 8pc of workforce, ASX finishes flat — as it happened

February 28, 2024 | fool.com.au

Why is this ASX 200 pharmaceuticals stock crashing 15% today?

February 16, 2024 | msn.com

Neuren (NEU) Shares Plunge as Short Seller Targets Partner Acadia

February 15, 2024 | fool.com.au

This ASX 200 healthcare share is diving 13% as short sellers take aim

January 18, 2024 | forbes.com

Stock Market Outlook In 2024

January 15, 2024 | markets.businessinsider.com

Jefferies Keeps Their Buy Rating on Clinuvel Pharmaceuticals Limited (CLVLF)

January 12, 2024 | fool.com.au

3 pharma shares outshining the ASX index today

January 8, 2024 | fool.com.au

The Neuren Pharmaceuticals share price is up 100% in 3 months: Can it keep rising?

January 6, 2024 | fool.com.au

The No. 1 ASX 200 shares of each market sector in 2023

January 4, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Innovent Biologics (IVBXF), Telix Pharmaceuticals Ltd. (TLPPF)

December 26, 2023 | finance.yahoo.com

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 44% Undervalued

December 22, 2023 | fool.com.au

Why Boss Energy, Lynas, Neuren, and Ora Banda shares are rising today

December 19, 2023 | au.investing.com

Neuren Pharmaceuticals' shares surge on positive Phase 2 clinical trial results

December 18, 2023 | fool.com.au

Guess which ASX 200 stock was just upgraded and tipped to rise 20%+

December 17, 2023 | fool.com.au

Why is this ASX 200 healthcare stock surging 32% on Monday?

December 13, 2023 | finance.yahoo.com

Australia Shares Rise, Helped by Healthcare Stocks

December 10, 2023 | afr.com

New fund targets companies battered by market doubts

November 6, 2023 | morningstar.com

Neuren Pharmaceuticals Ltd NEU

See More Headlines

Receive NEU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuren Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2019
Today: 4/16/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: ASX:NEU
CUSIP: N/A
CIK: N/A
Web: www.neurenpharma.com
Phone: 61 3 9092 0480
Fax: N/A
Employees: 2,105
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): A$1.20
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $157.08 million
Net Margins: 67.72%
Pretax Margin: N/A
Return on Equity: 127.30%
Return on Assets: 85.52%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.78
Quick Ratio: 31.54

Sales & Book Value

Annual Sales: $231.94 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 12.46
Book Value: A$1.61 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 129,950,000
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 1.99

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Jonathan Charles Pilcher A.C.A.
ACA, B.Sc., BSc (Hons), F.C.A., CEO, MD & Executive Director
Ms. Lauren Frazer C.A.
CFO & Company Secretary
Mr. Lawrence Glass BA (Biology)
Chief Science Officer
Mr. Gerry Zhao
Vice President of Corporate Development
Dr. Liza A. Squires M.D.
Chief Medical Officer

Key Competitors

View All Competitors

Insiders

NEU Stock Analysis - Frequently Asked Questions

How were Neuren Pharmaceuticals' earnings last quarter?: Neuren Pharmaceuticals Limited (ASX:NEU) released its earnings results on Wednesday, February, 27th. The company reported $0.03 earnings per share (EPS) for the quarter. Neuren Pharmaceuticals had a trailing twelve-month return on equity of 127.30% and a net margin of 67.72%.
What other stocks do shareholders of Neuren Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Neuren Pharmaceuticals investors own include Macquarie Group (MQG), Magellan Financial Group (MFG), Medlab Clinical (MDC), FBR (FBR), Embark Early Education (EVO), Dacian Gold (DCN), Constellation Technologies (CT1), Afterpay (APT) and Alkane Resources (ALK).

This page (ASX:NEU) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial